TY - JOUR
T1 - Public perceptions of radiofrequency ablation versus standard surgery for benign thyroid nodules
AU - Ding, Andy S.
AU - Xie, Deborah X.
AU - Zhang, Lisa
AU - Creighton, Francis X.
AU - Russell, Jonathon O.
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/7
Y1 - 2022/7
N2 - Background: Ultrasound-guided radiofrequency ablation has shown promising results for nonsurgical treatment of benign thyroid nodules. The purpose of this study is to investigate public perceptions of radiofrequency ablation and identify salient decision factors for benign thyroid nodules treatment. Methods: An internet-based survey was distributed via an online platform. Survey participants were prompted to envision having a benign thyroid nodules and were assessed on risk acceptance, willingness to pay, and importance of decision factors (eg, cost, risk, scarring) regarding treatment with either radiofrequency ablation or standard surgery. Results: A total of 830 respondents (male 46.3%, median age 35 years) were included. Respondents ranked the most important factors for benign thyroid nodules treatment as risk of missing cancer and risk of permanent hoarseness (mean score 5.23 and 4.50 out of 7, respectively). Female respondents ranked missing cancer higher in importance compared with other decision factors (coefficient = 0.251, P =.0002). Younger respondents (coefficient = 0.009, P =.014) or those with higher education levels (coefficient = 0.092, P =.010) ranked having a scar as a more important decision factor. Prior scars were associated with choosing a nonsurgical procedure over surgery (coefficient = 0.478, P =.00), even if scars were well-healed (coefficient = 0.781, P <.0001). On average, respondents are willing to pay less for radiofrequency ablation than for standard surgery (radiofrequency ablation: $7,612.44 vs surgery: $8,298.50; P <.0001). Conclusion: Respondents identified risk of missing cancer and risk of permanent hoarseness as the most important decision factors for benign thyroid nodules treatment. Education level and history of previous scars are both associated with a proclivity toward nonsurgical treatment and radiofrequency ablation.
AB - Background: Ultrasound-guided radiofrequency ablation has shown promising results for nonsurgical treatment of benign thyroid nodules. The purpose of this study is to investigate public perceptions of radiofrequency ablation and identify salient decision factors for benign thyroid nodules treatment. Methods: An internet-based survey was distributed via an online platform. Survey participants were prompted to envision having a benign thyroid nodules and were assessed on risk acceptance, willingness to pay, and importance of decision factors (eg, cost, risk, scarring) regarding treatment with either radiofrequency ablation or standard surgery. Results: A total of 830 respondents (male 46.3%, median age 35 years) were included. Respondents ranked the most important factors for benign thyroid nodules treatment as risk of missing cancer and risk of permanent hoarseness (mean score 5.23 and 4.50 out of 7, respectively). Female respondents ranked missing cancer higher in importance compared with other decision factors (coefficient = 0.251, P =.0002). Younger respondents (coefficient = 0.009, P =.014) or those with higher education levels (coefficient = 0.092, P =.010) ranked having a scar as a more important decision factor. Prior scars were associated with choosing a nonsurgical procedure over surgery (coefficient = 0.478, P =.00), even if scars were well-healed (coefficient = 0.781, P <.0001). On average, respondents are willing to pay less for radiofrequency ablation than for standard surgery (radiofrequency ablation: $7,612.44 vs surgery: $8,298.50; P <.0001). Conclusion: Respondents identified risk of missing cancer and risk of permanent hoarseness as the most important decision factors for benign thyroid nodules treatment. Education level and history of previous scars are both associated with a proclivity toward nonsurgical treatment and radiofrequency ablation.
UR - http://www.scopus.com/inward/record.url?scp=85125850137&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125850137&partnerID=8YFLogxK
U2 - 10.1016/j.surg.2022.01.031
DO - 10.1016/j.surg.2022.01.031
M3 - Article
C2 - 35248364
AN - SCOPUS:85125850137
SN - 0039-6060
VL - 172
SP - 110
EP - 117
JO - Surgery
JF - Surgery
IS - 1
ER -